Einige Inhalte dieser Seite sind nur für Abonnenten sichtbar.       Anmelden     oder      Jetzt abonnieren!

Archiv: Unternehmen

Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1) » Report
SGS Consolidates Leading Positions in Digital Trust and Connectivity with Granite River Labs Services Acquisition » SGS
Helvetia Asset Management AG: The fund management company of Helvetia (CH) Swiss Property Fund announces conditions of planned capital increase » Report
Helvetia Asset Management AG: La direction du fonds d’Helvetia (CH) Swiss Property Fund annonce les conditions de l’augmentation de capital prévue » Report
Helvetia Asset Management AG: Fondsleitung des Helvetia (CH) Swiss Property Fund gibt Konditionen der geplanten Kapitalerhöhung bekannt » Report
ARYZTA AG 2025 annual results » Report
Raiffeisen Schweiz verkauft grossen Teil ihrer Leonteq-Aktien » Report
PURE Funds AG: PURE Swiss Opportunity REF (PSO) erwirbt fünf attraktive Liegenschaften in Zürich – Portfolioziele 2025 übertroffen » Report
GURIT REPORTS NET SALES OF CHF 319.6M AND AN ADJUSTED OPERATING RESULT MARGIN OF 8.1% FOR 2025, SUCCESSFULLY DELIVERING A YEAR OF TRANSFORMATION » Report
SF Urban Properties Ltd – Annual Results 2025: Portfolio Rotation Delivers Initial Results » SF Urban
SF Urban Properties SA – Résultat annuel 2025 : la rotation du portefeuille montre ses premiers résultats » SF Urban
SF Urban Properties AG – Jahresergebnis 2025: Portfoliorotation zeigt erste Erfolge » SF Urban
Leonteq AG Press release: Raiffeisen sells majority of its stake in Leonteq » Report
Leonteq AG Medienmitteilung: Raiffeisen verkauft Grossteil ihrer Leonteq-Beteiligung » Report
Avolta completes cancellation of 4.9 million shares » Report
INFICON Expands Global Partnership with Oneida Research Services to Ensure Long-Term Customer Support » Report
FINMA-Verfahren: MBaer Merchant Bank AG in Liquidation » Report
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy » Report
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU) » Report
Partners Group to sell atNorth for an EV of USD 4 billion » Report